Terry Chrisomalis | TalkMarkets | Page 1
Pharma/Biotech Analyst
I am a graduate of Industrial and Business Service Management. I have been investing and writing about biotechnology stocks for many years now and have extensive experience writing about the science and companies themselves. I am a contributor to more

All Contributions

Latest Posts
1 to 16 of 353 Posts
1 2 3 ... 23 >>>
Protalix BioTherapeutics Pipeline Progress
Protalix Biotherapeutics (PLX) offers great potential in the coming months as its lead candidate, PLX-102 - a therapy for Fabry disease, is edging closer to the finish line.
Exclusive Interview With Lindsay Rosenwald, CEO Of Fortress Biotech 
I recently had the opportunity to interview Lindsay A. Rosenwald, CEO of Fortress Biotech, Inc. (FBIO), an innovative biopharmaceutical company.
Matinas Biopharma Is Highly Undervalued
With cash concerns put to rest, a solid lead product MAT9001, and a unique lipid nano-crystal delivery technology, I believe Matinas Biopharma is highly undervalued.
Bellicum Is Worth A Look With Multiple Catalysts On The Way In 2nd Half Of 2019
Bellicum is a highly undervalued biotech. Especially, when you consider that it has two types of technology that can be utilized to potentially alter how CAR-T therapies are produced.
Finally A Real Cancer Diagnosis Breakthrough?
TOMDF is a diagnostics company that utilizes blood tests for early detection of cancer and neurodegenerative diseases. But is it a good investment? I took a deeper look and reached out to the company's CEO, Herman Weiss, to get the facts.
Rexahn's Deal With China For RX-3117 Candidate Moves It Back On The Right Track
Rexahn Pharma generates a deal in Greater China for its clinical cancer product. Here's what you need to know...
CVR Medical: A New Approach To Cardiovascular Care
CVR Medical's proprietary device could change the spectrum of stroke prevention and diagnostics.
VistaGen Therapeutics: Interesting Prospects
VistaGen's drug AV-101 has breakthrough potential for treatment of depression and other indications.
OncoSec Raising Its Profile In Fight Against Cancer
New trials expect to build on previous results to quickly gain FDA approval.
20 Questions For NuLife Sciences CEO John B. Hollister
An inside look at a small company looking to have a big impact in transplant technology.
Teva Pharmaceuticals Posts Positive Phase 3 Results In Migraine Study
The drug that was tested in the phase 3 trial in patients with migraine is known as fremanezumab. With the positive phase 3 results, the company is looking to submit the Biologics License Application — BLA — to the FDA .
Inovio Pharmaceuticals Surges Higher On Positive HIV Vaccine Results
Recently Inovio Pharmaceuticals (INO) announced positive results for an early stage HIV vaccine study. The vaccine produced one of the best immune responses seen to date in a human HIV clinical trial.
EnteroMedics Acquires Medical Device Producer BarioSurg
Around 1.38 mil will be in in EnteroMedics common shares, and up to 1 million in convertible preferred shares. Through the acquisition, the Vest System and its vBloc product can be combined to create improved weight loss options.
Puma Biotechnology Soars After Positive Briefing Documents By FDA For Neratinib
Puma Biotechnology stock soars 50% on release of positive briefing docs but analysts still warn that approval is no sure thing.
GlycoMimetics Surges 100% On Breakthrough Therapy Designation
On Thursday, GlycoMimetics surged as high 100% after the company announced that it had received FDA breakthrough therapy designation.
AstraZeneca Achieves Positive Phase 3 Results In Late Stage Cancer Trial
On Friday, AstraZeneca announced that it had achieved positive results in a phase 3 lung cancer study. The key drug used in the trial, Imfinzi, was shown to greatly cut the risk of death in lung cancer patients.
1 to 16 of 353 Posts
1 2 3 ... 23 >>>